CMB Medicina, developing advanced therapy medicines, starts its establishment in VCIIP
Another biotechnology company, “CMB Medicina”, carrying out activities in the fields of tissue bank, development of advanced therapy medicinal products, and health technology research is starting its establishment in Vilnius City Innovation Industrial Park.
The agreement signed between Northtown Vilnius, the operator of Vilnius City Innovation Industrial Park (VCIIP), and CMB Medicina envisages that the company will develop projects on immunotherapy, regenerative medicine, tissue bank, development of biosimilars, recombinant proteins research and production. By 2025 the biotechnology company plans to invest more than Eur 5 million in R&D and production infrastructure, meeting the requirements of good manufacturing and laboratory practice at VCIIP.
“For the past three years, we have been implementing a number of projects with our partners – Froceth, Innovita Research, Imunolita, the National Cancer Institute and others – in the areas of tissue bank, advanced therapy medicinal products and the development of biosimilar products. These are very fast-growing health technology and biotechnology sectors. And it is in these areas that we will be developing at VCIIP that we already have exceptional experience: the achievements of CMB Medicina and partner researchers in the development of advanced therapy medicinal products (ATMP) are significant and important not only in Lithuania but also in the EU” – says the founder of CMB Medicina and manager of the project at VCIIP dr. Adas Darinskas.
According to Milda Gritėnaitė, the director of CMB Medicina, the founders and employees of the company have accumulated a great deal of scientific experience, constantly carrying out and supervising various biomedical projects, and have successful experience in developing innovative companies in the field of health technologies. “When planning the development at Vilnius City Innovation Industrial Park, we first thought about the concentration of activities and synergies with partners, which is a very important factor in offering competitive high value-added products to the market,” she says.
Dr. Adas Darinskas says, the main goal of the project at VCIIP is to create R&D and production infrastructure that meets the requirements of good manufacturing practice and good laboratory practice, which will allow to overcome the operating constraints of the existing infrastructure and allow faster development of the company.
According to Dr. Gediminas Pauliukevičius, head of Northtown Vilnius, the operator of the Vilnius City Innovation Industrial Park, CMB Medicina is a strong and rapidly growing innovator, distinguished by its ability to purposefully use the networking and synergy opportunities. “I have no doubt that both the development of CMB Medicina and the cluster they are developing will be a strong impetus for even more intensive cooperation between life sciences companies developing their activities at VCIIP and the development of innovative products in the field of health technologies,” says G. Pauliukevičius.
By the beginning of 2022, 17 companies have been established or have started to establish in the Vilnius City Innovation Industrial Park, developing activities in the fields of life sciences, new production processes, materials and technologies, energy and sustainable environment. UAB CMB medicina is the seventh biotechnology company to develop its activities in the neighbourhood of such life sciences companies as Biotecha, Experimentica, Gensinta, Immunodiagnostika, Stem Cell Research Center and Sanobiotec. 6 clusters have been established in Vilnius City Innovation Industrial Park, 4 of which operate in the field of life sciences.